

BEFORE THE  
SCIENTIFIC AND MEDICAL RESEARCH FUNDING WORKING GROUP  
TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE  
ORGANIZED PURSUANT TO THE  
CALIFORNIA STEM CELL RESEARCH AND CURES ACT  
REGULAR MEETING

LOCATION: 1625 POST STREET  
SAN FRANCISCO, CALIFORNIA

DATE: WEDNESDAY, NOVEMBER 28, 2007  
8 A.M.

REPORTER: BETH C. DRAIN, CSR  
CSR. NO. 7152

BRS FILE NO. : 80207

# BARRISTERS' REPORTING SERVICE

## I N D E X

ITEM	DESCRIPTION	PAGE NO.
CALL TO ORDER		3
ROLL CALL		3
ORIENTATION AND CHARGE OF THE WORKING GROUP		8
PUBLIC COMMENT		NONE
REMAINDER OF AGENDA HELD IN CLOSED SESSION		

**BARRISTERS' REPORTING SERVICE**

1 SAN FRANCISCO, CALIFORNIA; WEDNESDAY, NOVEMBER 28, 2007

2 8 A.M.

3

4 CHAIRMAN BRIVANLOU: I THINK IT'S TIME TO CALL  
5 TO ORDER THIS MEETING. MY NAME IS ALI BRIVANLOU. I'M A  
6 PROFESSOR AT THE ROCKEFELLER UNIVERSITY, AND I'M  
7 SUBSTITUTING FOR DR. DENNIS STEINDLER, WHO COULD NOT MAKE  
8 IT IN THE LAST MINUTE IN THE CHAIR OF THIS SESSION. I'M  
9 GOING TO BEGIN WITH THE ROLL CALL. SO, GIL, CAN WE GO  
10 FOR ROLL CALL, PLEASE.

11 DR. SAMBRANO: OKAY. THANK YOU. WHEN I CALL  
12 YOUR NAME, PLEASE SAY HERE. PATRICIA DONAHOE. MARCY  
13 FEIT. SHELLY HEIMFELD.

14 DR. HEIMFELD: HERE.

15 DR. SAMBRANO: ROBERT KLEIN.

16 MR. KLEIN: HERE.

17 DR. SAMBRANO: DIANE KRAUSE.

18 DR. KRAUSE: HERE.

19 DR. SAMBRANO: JOANNE KURTSBERG.

20 DR. KURTSBERG: HERE.

21 DR. SAMBRANO: ED PENHOET. JOAN SAMUELSON.

22 DAVID SERRANO-SEWELL. JEFF SHEEHY. JON SHESTACK. JON  
23 SHESTACK. HARINDER SINGH.

24 DR. SINGH: HERE.

25 DR. SAMBRANO: JOHN SLADEK.

## BARRISTERS' REPORTING SERVICE

1 DR. SLADEK: HERE.

2 DR. SAMBRANO: RAINER STORB.

3 DR. STORB: HERE.

4 DR. SAMBRANO: LORENZ STUDER.

5 DR. STUDER: HERE.

6 DR. SAMBRANO: JOHN WAGNER.

7 DR. WAGNER: HERE.

8 DR. SAMBRANO: DAVID WILLIAMS. JANET WRIGHT.

9 DR. WRIGHT: HERE.

10 DR. SAMBRANO: WISE YOUNG.

11 DR. YOUNG: HERE.

12 DR. SAMBRANO: THOMAS ZWAKA.

13 DR. ZWAKA: YES.

14 CHAIRMAN BRIVANLOU: OKAY. SO I WOULD LIKE TO  
15 WELCOME ALL OF YOU TO THIS FIRST PART OF THE PUBLIC  
16 SESSION. AND FIRST, OF COURSE, THIS IS A VERY IMPORTANT  
17 MOMENT IN THE HISTORY OF CIRM. AND FOR THOSE OF US WHO  
18 HAVE FOLLOWED IT FOR A LONG TIME, THAT REPRESENTS A MAJOR  
19 TRANSITION, AND I'M VERY PROUD TO BE PART OF THIS FOR A  
20 LITTLE WHILE NOW.

21 I'M GOING TO INTRODUCE THE INTERIM PRESIDENT OF  
22 CIRM, DR. MURPHY, WHO, IN TURN, IS GOING TO INTRODUCE THE  
23 NEW PRESIDENT OF CIRM.

24 DR. MURPHY: WE ARE LOUSY WITH PRESIDENTS  
25 TODAY. LET ME WELCOME ALL THE MEMBERS OF THE GRANTS

## BARRISTERS' REPORTING SERVICE

1 WORKING GROUP. THIS REALLY IS A HISTORICAL COMPETITION  
2 WE'RE HAVING FOR THE BEGINNING OF OUR MAJOR FACILITIES  
3 COMPETITION.

4 AS YOU KNOW, THIS COMPETITION WAS REALLY  
5 MANDATED BY THE FACT THAT WE NEED TO HAVE SPACE, OUR  
6 ORGANIZATIONS NEED TO HAVE SPACE TO CARRY OUT THE  
7 IMPORTANT WORK THAT THEY'RE DOING ON HUMAN EMBRYONIC STEM  
8 CELLS. LAST WEEK WAS A VERY IMPORTANT WEEK THAT WE ALL  
9 NOTED WITH THE RELEASE OF THE PAPERS ON HUMAN-INDUCED  
10 PLURIPOTENT STEM CELLS. AND I THINK WHAT THOSE FINDINGS  
11 DO IS REALLY EMPHASIZE THE NEED THAT THE FIELD HAS, NOT  
12 ONLY TO PURSUE THOSE CELLS, BUT ALSO TO CONTINUE PURSUING  
13 WORK ON HUMAN EMBRYONIC STEM CELLS, WHICH ARE REALLY THE  
14 GOLD STANDARD FOR THE FIELD.

15 AND I THINK THAT IN CIRM WE FEEL VERY STRONGLY  
16 THAT TO REALLY ACHIEVE THE POTENTIAL OF STEM CELL  
17 BIOLOGY, WE'RE GOING TO HAVE TO PURSUE TWO VERY IMPORTANT  
18 DIRECTIONS IN STEM CELL RESEARCH; THAT IS, THE INDUCED  
19 PLURIPOTENT CELLS AND THE MORE TRADITIONAL HUMAN  
20 EMBRYONIC STEM CELLS AND ALSO NUCLEAR TRANSFER.

21 AND THE FACILITIES THAT WE'RE TALKING ABOUT  
22 WILL FACILITATE, I THINK, THE RESEARCH IN BOTH OF THOSE  
23 AREAS. SO WE THANK YOU FOR BEING HERE. AND WE ALSO  
24 THANK YOU FOR ALL THE WORK THAT YOU'VE PUT IN PRIOR TO  
25 COMING HERE. WE ARE VERY MINDFUL OF THE FACT THAT IT

## BARRISTERS' REPORTING SERVICE

1 TAKES DAYS AND DAYS FOR YOU TO CAREFULLY EVALUATE THE  
2 GRANTS IN FRONT OF YOU TODAY, AND WE APPRECIATE ALL OF  
3 THAT EFFORT.

4 I'D ALSO LIKE NOW TO INTRODUCE DR. ALAN  
5 TROUNSON. ALAN, AS YOU KNOW, WILL BECOME THE PERMANENT  
6 PRESIDENT OF CIRM LITERALLY WITHIN THE MONTH, AND WE ARE  
7 DELIGHTED TO HAVE ATTRACTED HIM TO CALIFORNIA FROM  
8 AUSTRALIA. AND WE WELCOME YOU, ALAN, TO THIS FIRST  
9 COMPETITION THAT YOU WILL BE ATTENDING.

10 DR. TROUNSON: THANK YOU VERY MUCH, RICH. IT'S  
11 A PLEASURE TO BE HERE, AND WE'VE WORKED TOGETHER VERY  
12 CLOSELY. JUST FOR EVERYBODY'S INFORMATION, DR. MURPHY  
13 AND I HAVE WORKED CLOSELY AND WE KEEP UP A DIALOGUE  
14 TOGETHER, SO I KNOW EXACTLY WHERE HE'S SETTING THE PACE,  
15 AND I'M VERY SUPPORTIVE OF HIM, THE DIRECTION HE'S TAKING  
16 CIRM. DURING THIS PERIOD OF TIME, I THINK HE'S DONE A  
17 FANTASTIC JOB.

18 THE WORKING PARTY, I JUST KNOW WHAT IT'S LIKE  
19 TO BE ON A WORKING PARTY AND THE AMOUNT OF EFFORT THAT  
20 YOU HAVE TO PUT IN AND THE LATE NIGHTS AND, YOU KNOW, THE  
21 NEED TO GO TO THE LITERATURE AT TIMES TO FIND YOUR WAY.  
22 I THINK IT'S FANTASTIC THAT YOU PUT IN THIS EFFORT FOR US  
23 FOR THE WHOLE FIELD.

24 AND I THINK WE NEED TO RECOGNIZE THE STAFF AT  
25 CIRM BECAUSE I KNOW THAT THEY HAVE PUT AN ENORMOUS AMOUNT

## BARRISTERS' REPORTING SERVICE

1 OF EFFORT TO GET THE MATERIAL TO YOU AND TO ORGANIZE THE  
2 WHOLE REVIEW, AND THEY ARE REALLY UNDER THE PUMP, AS WE  
3 CALL IT. AND I THINK WE NEED TO RECOGNIZE THE EFFORTS OF  
4 BOTH THE WORKING PARTY AND THE TEAM DOING THIS.

5 I LOOK FORWARD TO GETTING HERE AT THE END OF  
6 DECEMBER AND BECOMING A PERMANENT MEMBER OF CIRM. AT THE  
7 MOMENT I'M KIND OF HALF AND HALF, AND THE HALF THAT'S  
8 HERE WITH YOU GUYS IS AN IMPORTANT PART FOR ME, BUT  
9 THERE'S A NEED TO EXTRADITE MYSELF FROM A LONG CAREER IN  
10 SCIENCE. AND THAT'S A BIT BITTERSWEET FOR ME BECAUSE  
11 IT'S ONE OF THOSE YEARS THAT I ENDED UP WITH FOUR NEW  
12 GRANTS AND A NUMBER OF TOP-LINE PAPERS. SO, YOU KNOW, IT  
13 LOOKED LIKE THE CAREER WAS STILL OKAY AT THAT TIME. SO  
14 IT'S A GREAT PLEASURE TO BE HERE. I HOPE I CAN ADD A  
15 LITTLE TO THE CONSIDERATIONS, BUT I'LL BE INTERESTED TO  
16 LISTEN TO YOUR REVIEWS.

17 AND I WISH EVERYBODY THE BEST AND HOPE IT'S  
18 GOING TO BE AN ENJOYABLE TIME BECAUSE WHAT I'VE READ OF  
19 THESE PROPOSALS, THEY'RE TERRIFIC AND INTERESTING. AND,  
20 OF COURSE, WE HAVE TO HAVE SOME SORT OF SELECTION PROCESS  
21 HERE, SO I GUESS SOME INSTITUTIONS MIGHT BE MISSING OUT.  
22 AND SO THE IMPORTANT PART IS TO DECIDE, YOU KNOW, HOW TO  
23 MAKE A DIFFERENCE BETWEEN THOSE THAT ARE FUNDED AND THOSE  
24 THAT ARE NOT. SO, MR. CHAIRMAN, THANK YOU VERY MUCH.

25 CHAIRMAN BRI VANLOU: THANK YOU AND WELCOME,

## BARRISTERS' REPORTING SERVICE

1 MR. PRESIDENT. SO WE'RE GOING TO MOVE NOW TO A  
2 PRESENTATION BY TAMAR PACTHER, AND I THINK THIS  
3 PRESENTATION IS PERFECTLY ON TIME BECAUSE IT'S GOING TO  
4 REMIND MOST OF US WHAT THE RULES AND THE ORIENTATION AND  
5 THE CHARGE OF THE WORKING GROUPS HAS BEEN AND I THINK IT  
6 IS, AND WE'RE LOOKING FORWARD TO YOUR PRESENTATION.

7 MS. PACTHER: THANK YOU VERY MUCH, MR.  
8 CHAIRMAN. I DID THIS FOR THE FACILITIES WORKING GROUP,  
9 SO I APOLOGIZE TO THE PATIENT ADVOCATES WHO'VE HEARD A  
10 VERSION OF THIS. AS YOU CAN SEE, I'M SOMEWHAT SLIDE  
11 IMPAIRED BECAUSE IT STILL SAYS FACILITIES WORKING GROUP  
12 ON THE FOOTER, BUT THIS HAS BEEN REVISED FOR THE GRANTS  
13 WORKING GROUP. SO I'M GOING TO TRY TO KEEP THIS UNDER  
14 TEN MINUTES, AND YOU SHOULD JUMP IN WHENEVER YOU HAVE ANY  
15 QUESTIONS.

16 I WANT TO GIVE YOU AN OVERVIEW OF WHAT I'M  
17 GOING TO BE TALKING ABOUT THIS MORNING. FIRST, THE  
18 OVERALL STRUCTURE AND FUNCTIONS OF CIRM, THE INSTITUTE,  
19 WHICH IS MADE UP OF THE ICOC, THE STAFF OF THE INSTITUTE,  
20 AND THE WORKING GROUPS. I'LL GO ON TO DISCUSS THE  
21 FUNCTIONS OF THE GRANTS WORKING GROUP, ITS STRUCTURE,  
22 GOVERNANCE, AND ITS RECORDS. AND FINALLY, A QUICK  
23 OVERVIEW OF WHAT YOU KNOW BEST, THE PROCESS OF GRANT  
24 REVIEW.

25 CIRM WAS CREATED IN NOVEMBER 2004 WHEN THE



## BARRISTERS' REPORTING SERVICE

1 CALIFORNIA VOTERS ADOPTED PROPOSITION 71. ITS PURPOSE IS  
2 TO FUND GRANTS AND LOANS FOR STEM CELL RESEARCH AND  
3 RESEARCH FACILITIES, WHICH IS WHY WE'RE HERE TODAY, IN  
4 THE HOPE OF FINDING CURES FOR DISEASES AND INJURIES THAT  
5 AFFLICT CALIFORNIANS.

6 THE ICOC IS THE GOVERNING BOARD FOR CIRM. IT'S  
7 MADE UP OF 29 MEMBERS APPOINTED BY VARIOUS ELECTED  
8 OFFICIALS IN THE STATE OF CALIFORNIA AND INCLUDES PATIENT  
9 ADVOCATES, UNIVERSITY OFFICIALS, AND BUSINESS EXECUTIVES  
10 WHO ARE PARTICULARLY INTERESTED IN AND KNOWLEDGEABLE  
11 ABOUT STEM CELL SCIENCE. ALL OF THESE MEMBERS ARE  
12 VOLUNTEERS.

13 THE ICOC APPOINTS THE PRESIDENT OF CIRM, WHO  
14 SERVES AT THE PLEASURE OF THE ICOC. CIRM STAFF IS HEADED  
15 BY THE PRESIDENT, AND WE'RE LIMITED TO 50 FULL-TIME  
16 EQUIVALENT. CURRENTLY WE'RE AT 26. WE'RE LOW BECAUSE,  
17 AS MANY OF YOU KNOW, OUR FUNDING WAS HELD UP BY  
18 LITIGATION UNTIL THE MIDDLE OF THIS YEAR. SO WE'RE  
19 CURRENTLY TRYING TO RAMP UP FROM 26 TO A FULL 50. SO  
20 APPRECIATE HOW A LITTLE STAFF HAS BEEN HELPING TO PREPARE  
21 FOR THESE MEETINGS. STAFF SERVES AT THE PLEASURE OF THE  
22 PRESIDENT, BUT ARE EXEMPT FROM THE NORMAL CIVIL SERVICE  
23 RULES THAT APPLY TO MOST STATE EMPLOYEES. AND MOST OF  
24 OUR STAFF IS DEVOTED TO SCIENTIFIC STAFF. WE ALSO HAVE  
25 SUPPORT IN FINANCE, ADMINISTRATION, AND LEGAL.

## BARRISTERS' REPORTING SERVICE

1 I WANTED TO GIVE YOU AN IDEA OF THE  
2 RESPONSIBILITIES OF THE PRESIDENT AND THE STAFF. WE  
3 PERFORM SUPPORT FUNCTIONS FOR THE WORKING GROUP  
4 RECRUITING MEMBERS, MAKING SURE THAT YOU ARE HAPPY AND  
5 HAVE WHAT YOU NEED, AND RUNNING THESE MEETINGS. AND WITH  
6 RESPECT TO THE ICOC, WE SUPPORT THEIR PROCESS OF ACTING  
7 ON THE RECOMMENDATIONS THAT ARE SUBMITTED AND  
8 IMPLEMENTING ITS DECISIONS, BOTH WITH RESPECT TO THE  
9 GRANTS AND POLICIES THAT IT ADOPTS.

10 OUR INDEPENDENT FUNCTIONS ARE IN MOVING THE  
11 PROCESS OF GRANT REVIEW ALONG AFTER APPROVAL: FUNDING  
12 ADMINISTRATION, MANAGEMENT AND COMPLIANCE WITH THE GRANT  
13 PROCESS WITH THE GRANTEES. WE ALSO WORK ON BUDGET AND  
14 COST CONTROL, AND WE WORK, ONCE WE HAVE THEM, WITH THE  
15 MANAGEMENT IN EXECUTION OF INTELLECTUAL PROPERTY  
16 AGREEMENTS AND OTHER CONTRACTS.

17 WE STAFF THE ICOC AND THE WORKING GROUPS AS  
18 ENTITIES. SO BECAUSE WE HAVE SO FEW STAFF, WE CAN'T  
19 STAFF INDIVIDUAL MEMBERS OF THE ICOC AND WORKING GROUPS,  
20 ALTHOUGH WE DO TRY TO PROVIDE WHATEVER SUPPORT YOU NEED  
21 WHEN YOU NEED IT. AND WE POOL ADMINISTRATIVE STAFF AT  
22 THE INSTITUTE, AND WE'RE HAPPY TO HELP YOU WHEN WE CAN  
23 WITH THAT AS WELL.

24 THERE ARE THREE WORKING GROUPS: GRANTS,  
25 STANDARDS, AND FACILITIES. THE FACILITIES WORKING GROUP

## BARRISTERS' REPORTING SERVICE

1 MET AFTER YOUR RECOMMENDATIONS ON THE SHARED LABS AND  
2 WILL MEET AFTER YOUR RECOMMENDATIONS ON THESE LARGE  
3 FACILITIES AS WELL. THERE ARE SOME COMMON FUNCTIONAL  
4 ATTRIBUTES OF THE WORKING GROUPS. THE MEMBERSHIP IS  
5 APPOINTED BY THE ICOC ACCORDING TO THE CRITERIA THAT ARE  
6 IN THE STATUTE. THEY'RE SCHEDULED TO MEET FOUR MEETINGS  
7 A YEAR. YOU MEET AT LEAST FOUR TIMES A YEAR, AND  
8 FACILITIES WILL MEET LESS SO BECAUSE MOST OF THEIR WORK  
9 WILL BE COMPLETED AFTER THIS ROUND.

10 THE CIRM STAFF COORDINATES AND HAS A DESIGNATED  
11 LIAISON TO EACH WORKING GROUP, AND EACH WORKING GROUP HAS  
12 A CHAIR AND VICE CHAIR WHO WORK WITH THE PRESIDENT,  
13 STAFF, AND ICOC TO PREPARE FOR THESE MEETINGS.

14 THERE ARE ALSO SOME COMMON RESTRICTIONS ON THE  
15 WORKING GROUPS. YOU ARE ADVISORY, NOT DECISION-MAKING  
16 BODIES. THE ICOC IS THE FINAL DECISION MAKER WITH  
17 RESPECT TO ALL DECISIONS AT THE AGENCY. AND THE WORKING  
18 GROUP RECOMMENDATIONS MUST BE REACHED BY A MAJORITY. AND  
19 THERE IS A PROVISION IN THE STATUTE FOR SUBMISSION TO THE  
20 ICOC OF A MINORITY REPORT, AND I THINK THIS GROUP HAS  
21 DONE THAT IN THE PAST. YOU ARE GOVERNED BY A CONFLICT OF  
22 INTEREST POLICY THAT WAS ADOPTED BY THE ICOC. AND AS  
23 WELL, EACH WORKING GROUP HAS ITS OWN SET OF BYLAWS. I'M  
24 SURE YOU READ THEM EVERY NIGHT BEFORE YOU GO TO BED. BUT  
25 YOU SHOULD AT LEAST READ THEM BEFORE YOU ENTER INTO A

## BARRISTERS' REPORTING SERVICE

1 REVIEW TO REMIND YOURSELF OF WHAT THOSE RESTRICTIONS ARE.

2 THE RECORDS OF THIS GROUP ARE GENERALLY NOT  
3 SUBJECT TO A PUBLIC RECORDS ACT REQUEST IN THE SAME WAY  
4 THAT ALL THE OTHER RECORDS OF A STATE AGENCY ARE. BUT  
5 THOSE RECORDS THAT GO TO THE ICOC ARE SUBJECT TO THAT  
6 KIND OF REQUEST AND GENERALLY WILL BECOME PUBLIC  
7 INFORMATION.

8 WITH RESPECT SPECIFICALLY TO THE GRANTS WORKING  
9 GROUP, THE STATUTE PROVIDES THAT THERE ARE SEVEN PATIENT  
10 ADVOCATE MEMBERS OF THIS GROUP, 15 STEM CELL SCIENTISTS,  
11 AND THE ICOC CHAIR. IN ADDITION, WE HAVE ALTERNATE AND  
12 AD HOC SCIENTIST MEMBERS WHO THE ICOC MUST APPOINT  
13 ACCORDING TO THE SAME CRITERIA TO WHICH YOU ARE  
14 APPOINTED. AND STAFF WILL ASSIGN THEM TO SERVE IF ONE OF  
15 YOU CAN'T SERVE OR IS RECUSED FOR ANY REASON. THOSE  
16 MEMBERS, ALTERNATES AND AD HOCS, MAY VOTE IN PLACE OF ONE  
17 OF YOU. THERE ARE ALSO NONVOTING SCIENTIST SPECIALISTS  
18 WHO STAFF CHOOSES AND ASSIGNS IF THEY HAVE A SPECIAL AREA  
19 OF EXPERTISE, AND THEY MAY NOT VOTE IN PLACE OF A REGULAR  
20 GRANTS WORKING GROUP MEMBER. THE NUMBER OF VOTING  
21 SCIENTISTS ON THIS GROUP CAN NEVER EXCEED 15.

22 SO THESE ARE THE BASIC FUNCTIONS OF THE GRANTS  
23 WORKING GROUP: TO COMPETITIVELY REVIEW APPLICATIONS AND  
24 RECOMMEND AWARDS TO THE ICOC, TO RECOMMEND THE CRITERIA,  
25 REQUIREMENTS, AND STANDARDS FOR FUNDING APPLICATIONS.

## BARRISTERS' REPORTING SERVICE

1 AND THAT WAS DONE EARLY ON WITH THE ADOPTION OF THE  
2 GRANTS ADMINISTRATION POLICY. TO RECOMMEND STANDARDS FOR  
3 THE OVERSIGHT OF AWARDS, ALSO THE GRANTS ADMINISTRATION  
4 POLICY, AND TO CONDUCT OVERSIGHT REVIEW AND RECOMMEND  
5 STANDARDS FOR EVALUATION OF GRANTEES. THAT WAS ALSO  
6 PARTIALLY INCLUDED IN THE GRANTS ADMINISTRATION POLICY.

7 THE COMPETITIVE REVIEW OF APPLICATIONS, AS YOU  
8 KNOW, IS DONE WHEN THE 15 SCIENTISTS SCORE THE  
9 APPLICATIONS FOR SCIENTIFIC MERIT BASED ON THESE  
10 STATUTORY CRITERIA. AND FOLLOWING THE SCIENTIFIC  
11 SCORING, THE ENTIRE WORKING GROUP CONDUCTS A PROGRAMMATIC  
12 REVIEW AND MAKES THE FUNDING RECOMMENDATIONS TO THE ICOC.

13 THERE ARE THREE SOURCES OF GOVERNANCE, AS I  
14 MENTIONED EARLIER, FOR THIS GROUP. FIRST IS PROP 71,  
15 SECOND ARE THE BYLAWS, AND THE CONFLICT OF INTEREST  
16 POLICY THAT WAS ADOPTED BY THE ICOC. AND IF ANY OF YOU  
17 LOOK AT THOSE DOCUMENTS AND THINK THERE NEED TO BE  
18 CHANGES, I'M CURRENTLY CONSIDERING OVERHAULING MANY OF  
19 THE INSTITUTE'S POLICIES. AND I WOULD BE INTERESTED IN  
20 KNOWING WHAT YOU FOUND HELPFUL AND WHAT NOT.

21 I JUST WANTED TO GIVE YOU SOME OF THE  
22 HIGHLIGHTS OF THE BYLAWS. IT PROVIDES THAT THE CHAIR FOR  
23 THE SCIENTIFIC REVIEW MUST COME FROM AMONG THE 15  
24 SCIENTISTS SITTING ON THE GRANTS WORKING GROUP TO CHAIR  
25 THE TECHNICAL REVIEW, AND THAT THE VICE CHAIR MUST BE

## BARRISTERS' REPORTING SERVICE

1 CHOSEN AMONG THE PATIENT ADVOCATES AND WILL CHAIR THE  
2 PROGRAMMATIC REVIEWS. YOUR BUSINESS IS TO BE CONDUCTED  
3 IN PUBLIC EXCEPT FOR REVIEW OF APPLICATIONS WHICH, SINCE  
4 THIS IS THE BULK OF YOUR WORK, IS USUALLY NOT DONE IN  
5 PUBLIC. AND A QUORUM IS BY STATUTE 65 PERCENT OF THE  
6 MEMBERS ELIGIBLE TO VOTE, WHICH IS WHY IT'S SO IMPORTANT  
7 THAT ALL OF YOU ATTEND.

8 THIS PART ABOUT PUBLIC MEETINGS, BECAUSE MOST  
9 OF YOUR WORK IS DONE IN CLOSED SESSION, APPLIES LESS TO  
10 YOU, BUT IT'S IMPORTANT TO THINK ABOUT THE PARTICULAR  
11 DEMANDS OF HOLDING MEETINGS IN PUBLIC, GETTING THROUGH  
12 THE WORK, PREPARING FOR THE WORK. THERE'S A CERTAIN  
13 AMOUNT OF FORMALITY THAT'S INVOLVED IN THAT THAT DOESN'T  
14 HAPPEN IN A CLOSED-SESSION MEETING. AND THE IMPORTANCE  
15 OF THAT FOR US IS TO HELP BUILD PUBLIC CONFIDENCE. WE'RE  
16 A NEW AGENCY IN THE STATE, AND PART OF WHAT WE'RE TRYING  
17 TO DO IS BE AS TRANSPARENT AS WE CAN BE WHILE STILL  
18 SERVING THE MISSION.

19 THE CONFLICT OF INTEREST POLICY, AGAIN, THE  
20 HIGHLIGHTS. THIS WAS ADOPTED BY THE ICOC. IT APPLIES  
21 ONLY TO THE SCIENTIST MEMBERS OF THIS GROUP BECAUSE THE  
22 ICOC MEMBERS, THE PATIENT ADVOCATES ARE GOVERNED BY A  
23 SEPARATE CONFLICT OF INTEREST POLICY THAT APPLIES TO ICOC  
24 MEMBERS. THE POLICY THAT APPLIES TO THE SCIENTISTS  
25 ADDRESS FINANCIAL, PROFESSIONAL, AND PERSONAL CONFLICT OF

## BARRISTERS' REPORTING SERVICE

1 INTERESTS. IT IS AUDITED BY CIRM STAFF ON A REGULAR  
2 BASIS AND IS ALSO SUBJECT TO AUDIT BY OUR BUREAU OF STATE  
3 AUDITS. AND IF A CONFLICT EXISTS, YOU MAY NOT  
4 PARTICIPATE IN ANY WAY IN THE DISCUSSION OR THE DECISION  
5 OF THE GRANTS WORKING GROUP, EITHER IN THE MEETING OR  
6 OUTSIDE IT. YOU JUST CAN'T PARTICIPATE IN ANY WAY BY  
7 DISCUSSING IT WITH ANY OF THE MEMBERS.

8 I WILL SKIP THIS ONE BECAUSE I WENT OVER IT A  
9 LITTLE BIT. MOST OF YOUR RECORDS ARE NOT PUBLIC.  
10 BRIEFLY, THE GRANT PROCESS OVERVIEW STARTS WHEN THE  
11 PRESIDENT OF CIRM PRESENTS TO THE ICOC FOR DISCUSSION A  
12 CONCEPT PLAN FOR A RESEARCH RFA. THEN THE STAFF DRAFTS  
13 AND ISSUES AN RFA AND AN APPLICATION AFTER RECEIVING  
14 CONCEPT APPROVAL FROM THE ICOC. FOLLOWING THAT, THE  
15 INSTITUTIONS SUBMIT APPLICATIONS TO CIRM IN RESPONSE TO  
16 THE RFA. THIS IS ALL DONE, AS MUCH AS POSSIBLE, ON  
17 COMPUTER AND DIGITALLY.

18 THE STAFF, WHEN IT RECEIVES THE APPLICATIONS,  
19 DISTRIBUTES ASSIGNMENTS TO PRIMARY AND SECONDARY  
20 REVIEWERS AND SCHEDULES THE MEETING LIKE THIS ONE. THE  
21 PRIMARY AND SECONDARY REVIEWERS SUBMIT PRELIMINARY SCORES  
22 AND WRITTEN REVIEWS POSTED ON A SECURE ONLINE SITE FOR  
23 ALL TO REVIEW. AND THEN YOU COME HERE AND CONFIDENTIALLY  
24 REVIEW APPLICATIONS ACCORDING TO THE DEMANDS OF THE  
25 PARTICULAR RFA AND THE APPROVED CRITERIA. THE SCIENTIFIC

## BARRISTERS' REPORTING SERVICE

1 CHAIR CONDUCTS A TECHNICAL REVIEW, AND THE VICE CHAIR  
2 CONDUCTS THE PROGRAMMATIC REVIEW.

3 FOLLOWING YOUR REVIEW, THE CIRM STAFF DRAFTS  
4 ABSTRACTS OF YOUR DISCUSSION AND RECOMMENDATIONS FOR THE  
5 ICOC'S CONSIDERATION AND POSTS A PUBLIC ABSTRACT. AND  
6 THAT'S WHAT IS PROVIDED TO THE ICOC. AND THEN THERE'S A  
7 PRIVATE ABSTRACT THAT'S PROVIDED TO THE APPLICANTS. THE  
8 ICOC THEN MEETS PUBLICLY TO CONSIDER YOUR RECOMMENDATIONS  
9 AND VOTES TO APPROVE APPLICATIONS FOR FUNDING.

10 ONCE APPLICATIONS ARE APPROVED FOR FUNDING, THE  
11 CIRM STAFF CONDUCTS ADMINISTRATIVE REVIEW. BECAUSE WE  
12 HAVE SO LITTLE STAFF, WE RESERVE THINGS LIKE ELIGIBILITY  
13 DETERMINATIONS UNTIL AFTER THE ICOC HAS APPROVED FOR  
14 FUNDING. THIS BECAME VERY IMPORTANT ESPECIALLY IN  
15 CONSIDERATION OF THE SEED AND COMPREHENSIVE GRANTS WHERE  
16 THERE WERE SO MANY APPLICATIONS THAT CAME IN AND  
17 RELATIVELY FEW APPROVED, SO WE JUST REVIEW THOSE THAT  
18 HAVE ACTUALLY BEEN APPROVED TO MAKE SURE THAT ELIGIBILITY  
19 CRITERIA ARE MET, AND GENERALLY THEY ARE.

20 ON SUCCESSFUL COMPLETION OF THAT ADMINISTRATIVE  
21 REVIEW, THE PRESIDENT ISSUES A NOTICE OF GRANT AWARD THAT  
22 APPLICANTS MUST SIGN AND RETURN TO CIRM. AND THEN WE ASK  
23 THE STATE CONTROLLER TO ISSUE A WARRANT FOR GRANT  
24 FUNDING, AND USUALLY THAT'S THE FIRST FULL YEAR OF GRANT  
25 FUNDING. AFTER INITIAL FUNDING, OUR SCIENTIFIC GRANTS



## BARRISTERS' REPORTING SERVICE

1 MANAGEMENT STAFF MONITOR THE GRANTS AND LOOK AT THE  
2 ANNUAL REPORTS AND REVIEW ANNUAL FINANCIAL DISCLOSURES.  
3 WE ARE ALSO RESPONSIBLE FOR AUDITING COMPLIANCE WITH THE  
4 GRANTS ADMINISTRATION POLICY AND HAVE THE AUTHORITY TO  
5 WITHHOLD FUNDS FOR FAILURE OF COMPLIANCE. AND WE REPORT  
6 REGULARLY TO THE ICOC ON THAT.

7 ARE THERE ANY QUESTIONS? I JUST WANT TO THANK  
8 YOU ALL VERY MUCH FOR SERVING.

9 CHAIRMAN BRIVANLOU: THERE'S ONE QUESTION HERE.

10 MR. KLEIN: TAMAR, I THINK IT'S IMPORTANT FOR  
11 THIS GROUP, SOME OF WHOM HAVE NOT BEEN PRESENT WHEN WE  
12 DID A MINORITY REPORT, TO UNDERSTAND CONCEPTUALLY. THE  
13 PURPOSE OF THAT IN THE INITIATIVE IS THAT BRILLIANT, NEW,  
14 EMERGING AREAS, EMERGING CONCEPTS NOT BE BURIED BY THE  
15 DOMINANT VIEW OF SCIENCE AT THE TIME SUCH THAT IF 35  
16 PERCENT OF THE WORKING GROUP CAN COALESCE ON A MINORITY  
17 POSITION, THAT MINORITY REPORT GOES TO THE FULL BOARD  
18 JUST AS IF IT WERE A MAJORITY REPORT EXCEPT IT'S  
19 SPECIFICALLY SHOWN TO REPRESENT JUST THE MINORITY THAT  
20 HAS SIGNED ONTO THAT REPORT.

21 THIS ALLOWS THE BOARD IN EXECUTIVE SESSION TO  
22 LOOK AT THIS AND IN PUBLIC SESSION TO DEBATE WHETHER OR  
23 NOT THE MINORITY POSITION THAT'S ADVOCATED SHOULD BE  
24 GIVEN AN OPPORTUNITY FOR FUNDING TO EXPLORE THIS  
25 PARTICULAR NEW THEORY THAT OTHERWISE MAY NOT BE

## BARRISTERS' REPORTING SERVICE

1 CONSISTENT WITH THE DOMINANT VIEW OF SCIENCE AND THE  
2 DOMINANT MOVEMENT OF SCIENCE ON THAT SPECIFIC TOPIC.

3 SO IT'S A VERY IMPORTANT RIGHT OF THE WORKING  
4 GROUP TO LOOK AT THAT OPPORTUNITY. AND AS TAMAR HAS  
5 SAID, THERE HAS BEEN A MINORITY REPORT PREVIOUSLY ISSUED  
6 BY ONE OF THE WORKING GROUP SESSIONS. AND I ACTUALLY  
7 BELIEVE THAT MINORITY REPORT WAS APPROVED AT THE BOARD  
8 LEVEL IN THAT PARTICULAR CASE.

9 SECONDLY, DEFINITIONS ARE IMPORTANT HERE,  
10 SOMETIMES UNUSUALLY IMPORTANT. AND WHEN IT SAYS THE  
11 MAJORITY IS TWO-THIRDS OF THOSE ELIGIBLE TO VOTE, I'D  
12 LIKE TO POINT OUT THAT ELIGIBLE IS A VERY IMPORTANT TERM  
13 BECAUSE WHENEVER SOMEONE IS RECUSED OR ANY GROUP OF  
14 INDIVIDUALS ARE RECUSED, OUR QUORUM NUMBERS AUTOMATICALLY  
15 RECALIBRATE. THIS IS TRUE AT THE WORKING GROUP; IT'S  
16 TRUE AT THE ICOC. SO WE HAVE FIVE PEOPLE WALKING OUT OF  
17 THE ROOM, WE DON'T LOSE OUR QUORUM. WE AUTOMATICALLY  
18 ADJUST THE BASE ON WHICH THE TWO-THIRDS VOTE IS --

19 MS. PACHTER: NOT TWO-THIRDS. MAJORITY OF A  
20 QUORUM.

21 MR. KLEIN: MAJORITY OF THE QUORUM IS  
22 CALCULATED, BUT OUR QUORUM NUMBER AUTOMATICALLY  
23 RECALCULATES.

24 SO IN TERMS OF OUR SESSIONS, IN ADDITION,  
25 TAMAR, YOU MIGHT COMMENT ON THE ISSUE, WHICH WON'T BE

## BARRISTERS' REPORTING SERVICE

1 PRESENT TODAY, ON THE ISSUE ON EMBRYONIC VERSUS ADULT  
2 STEM CELL RESEARCH, THE TWO-THIRDS VOTE BY THE WORKING  
3 GROUP FOR NONEMBRYONIC STEM CELL RESEARCH FOR THE  
4 RECOMMENDATION TO THE BOARD.

5 MS. PACHTER: YOU MEAN OTHER VITAL RESEARCH  
6 OPPORTUNITIES, THAT PIECE OF IT? SO THE STATUTE PROVIDES  
7 THAT PRIORITY MUST BE GIVEN TO RESEARCH THAT WOULD NOT  
8 OTHERWISE BE ADEQUATELY FUNDED BY THE FEDERAL GOVERNMENT.  
9 AND BROADLY SPEAKING, THAT'S EMBRYONIC STEM CELL  
10 RESEARCH. BUT THE STATUTE PERMITS THE ICOC TO FUND THE  
11 BROAD RANGE OF EMBRYONIC STEM CELL RESEARCH, SO THERE ARE  
12 A COUPLE OF QUALIFICATIONS ON THAT PRIORITY FOR --

13 MR. KLEIN: THE BROAD RANGE OF STEM CELL  
14 RESEARCH.

15 MS. PACHTER: -- THE RANGE OF STEM CELL  
16 RESEARCH; THAT'S RIGHT. PRIORITY FOR EMBRYONIC STEM CELL  
17 RESEARCH. ONE IS THAT THE PRIORITY IS FOR ANY RESEARCH  
18 THAT WOULD NOT BE ADEQUATELY FUNDED. SO THAT MEANS IF  
19 THE FEDERAL FUNDING LEVEL ISN'T SUFFICIENTLY HIGH, IF IT  
20 WOULDN'T COME SUFFICIENTLY FAST, THE ICOC HAS THE ABILITY  
21 TO FUND IT.

22 IT ALSO MEANS SPECIFICALLY THAT EVEN IF  
23 SOMETHING IS ADEQUATELY FUNDED BY THE FEDERAL GOVERNMENT,  
24 THIS GROUP BY A TWO-THIRDS MAJORITY CAN RECOMMEND TO THE  
25 ICOC THAT SOMETHING THAT IS BEING CURRENTLY FUNDED BY THE

## BARRISTERS' REPORTING SERVICE

1 FEDERAL GOVERNMENT ALSO BE FUNDED BY CIRM BECAUSE IT IS A  
2 VITAL RESEARCH OPPORTUNITY. AND THAT IS SPECIFICALLY  
3 PROVIDED FOR IN THE STATUTE, SO WE ARE NOT LIMITED HERE  
4 OR AT THE ICOC TO FUNDING EXCLUSIVELY EMBRYONIC STEM CELL  
5 RESEARCH.

6 THANK YOU VERY MUCH FOR BEING SO PATIENT. AND  
7 I, ESPECIALLY WITH RESPECT TO CONFLICT OF INTERESTS, IF  
8 ANY OF YOU EVER HAVE ANY QUESTIONS, PLEASE FEEL FREE TO  
9 CONTACT ME AND ASK QUESTIONS. AND WE THANK YOU AGAIN FOR  
10 YOUR SERVICE.

11 CHAIRMAN BRIVANLOU: THANK YOU VERY MUCH,  
12 TAMAR, FOR THIS VERY REFRESHING PRESENTATION AGAIN TO  
13 REMIND US OF THE RULES OF THE GAME. I'M GOING TO OPEN  
14 THE SESSION NOW FOR PUBLIC COMMENTS. IF THERE IS ANY  
15 COMMENTS FROM THE PUBLIC, NOW IS THE TIME. THERE ARE NO  
16 COMMENTS FROM THE PUBLIC, SO WE'RE GOING TO MOVE FORWARD.

17 ARE THERE ANY QUESTIONS FROM THE PANEL OR  
18 ISSUES THAT THE MEMBERS OF THE PANEL WOULD LIKE TO  
19 DISCUSS? DR. SINGH.

20 DR. SINGH: JUST ONE THOUGHT. I THINK THE  
21 PROVISION OF A MINORITY REPORT IS AN EXCEEDINGLY VALUABLE  
22 ONE, BUT I THINK THE THRESHOLD SEEMS TO BE SOMEWHAT HIGH.  
23 IF THE IDEA IS TO AT LEAST CONSIDER IDEAS OR PROPOSALS  
24 THAT ARE FAR FROM THE MAINSTREAM, I THINK IT GOES WITHOUT  
25 SAYING THAT IT'S LIKELY THAT IN A GROUP OF 15 OF US, VERY

## BARRISTERS' REPORTING SERVICE

1 FEW PEOPLE WOULD BE ENTHUSIASTIC ABOUT SUCH AN IDEA. AND  
2 SO 35 PERCENT WOULD BE A HIGH THRESHOLD TO MEET FOR  
3 OFF-THE-WALL, UNUSUAL IDEAS TO BE CONSIDERED SERIOUSLY BY  
4 THE GROUP.

5 SO I GUESS I WOULD ASK THAT AT SOME POINT ONE  
6 RECONSIDER WHAT THAT THRESHOLD OUGHT TO BE.

7 MR. KLEIN: THE OPPORTUNITY FOR A MINORITY  
8 REPORT ACTUALLY ARISES IN THE PROGRAMMATIC REVIEW. IN  
9 THE PROGRAMMATIC REVIEW, YOU HAVE THE BENEFIT OF THE  
10 PATIENT ADVOCATES AND THE SCIENTISTS. SO YOUR VOTING  
11 GROUP IS REALLY 21. AND IN THAT I WOULD ALWAYS HOPE WE  
12 HAD STRONG SCIENTIFIC LEADERSHIP AND STRONG SCIENTIFIC  
13 VALIDATION IN A MINORITY REPORT, BUT THE PATIENT  
14 ADVOCATES ARE AVAILABLE TO HELP FORM THAT MINORITY REPORT  
15 AS WELL.

16 THE PATIENT ADVOCATES ARE KNOWN AT TIMES TO BE  
17 COURAGEOUS. AND SO HOPEFULLY, WITH SOME STRONG  
18 SCIENTIFIC ADVOCATES, WE COULD GET THAT TO -- A CONSENSUS  
19 COULD BE FORMED. BUT IMPORTANTLY HERE, THE INITIATIVE,  
20 WHEN I WROTE IT, I DIDN'T HAVE THE BENEFIT OF THIS WHOLE  
21 GROUP'S ADVICE. AND IT IS IN THE INITIATIVE THAT IT  
22 TAKES A 35-PERCENT VOTE. WE ARE LEARNING EVERY DAY AS WE  
23 GO FORWARD. IT'S A VERY ORGANIC PROCESS, BUT I  
24 APPRECIATE THE ADVICE ON THAT.

25 I WOULD ALSO SAY, AS A MATTER OF PROFESSIONAL

**BARRISTERS' REPORTING SERVICE**

1 COURTESY, IT'S POSSIBLE THAT WITH STRONG SCIENTIFIC  
2 LEADERSHIP BY SEVERAL MEMBERS OF THE COMMITTEE, IN THE  
3 PRIOR MINORITY REPORT, I THINK WE SAW ONE OR TWO OTHER  
4 SCIENTISTS JOIN IN OUT OF RESPECT FOR THE FACT THAT THE  
5 IDEA SHOULD BE AT LEAST RAISED FOR CONSIDERATION.

6 CHAIRMAN BRIVANLOU: THANK YOU VERY MUCH, BOB  
7 KLEIN. IF THERE ARE NO OTHER ITEMS, I WOULD LIKE TO  
8 CLOSE THIS MEETING AND THANK ALL OF YOU FOR BEING HERE,  
9 FOR ALL YOUR EFFORTS FROM THE STAFF AND FROM THE WORKING  
10 GROUP, AND I'M LOOKING FORWARD TO SEE YOU AT THE ROOM  
11 NEXT DOOR IN A FEW MINUTES.

12 (THE OPEN SESSION WAS THEN CONCLUDED AT  
13 08:32 AM. THE REMAINDER OF THE MEETING WAS THEN HELD IN  
14 CLOSED SESSION.)

15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

REPORTER' S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE OPEN-SESSION PROCEEDINGS BEFORE THE SCIENTIFIC AND MEDICAL RESEARCH FUNDING WORKING GROUP OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD AT THE LOCATION INDICATED BELOW

1625 POST STREET  
SAN FRANCISCO, CALIFORNIA  
ON  
NOVEMBER 28, 2007

WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.



BETH C. DRAIN, CSR 7152  
BARRISTER' S REPORTING SERVICE  
1072 BRISTOL STREET  
SUITE 100  
COSTA MESA, CALIFORNIA 92606  
(714) 444-4100